Polyomaviruses and the risk of breast cancer: a systematic review and meta-analysis.

IF 3.1 2区医学 Q3 IMMUNOLOGY

Infectious Agents and Cancer Pub Date : 2025-03-04 DOI:10.1186/s13027-025-00644-4

Tahoora Mousavi, Fatemeh Shokoohy, Mahmood Moosazadeh

{"title":"Polyomaviruses and the risk of breast cancer: a systematic review and meta-analysis.","authors":"Tahoora Mousavi, Fatemeh Shokoohy, Mahmood Moosazadeh","doi":"10.1186/s13027-025-00644-4","DOIUrl":null,"url":null,"abstract":"Background: Breast cancer is a major global health problem worldwide, affecting more than 2.25 million women annually. The disease is influenced by various factors, including some viruses, gender, age, and family history. This study aimed to conducting a comprehensive systematic review and meta-analysis of existing studies on the polyomaviruses in breast cancer.Methods: This systematic review and meta-analysis aimed to provide an evidence-based analysis of the relationship between polyomaviruses and breast cancer. The global online databases were used to identify relevant studies published from 2000 to July 2024. The quality of each article was assessed using the Newcastle-Ottawa Scale (NOS) checklist. Data analysis was performed using STATA software, and standard errors of prevalence were calculated using the binomial distribution formula. Heterogeneity of study results was evaluated using the I-square and Q index, while publication bias was examined using the Begg's test. A random effects model was used to determine prevalence rates, and a forest plot diagram was used to present results with 95% confidence intervals. The Trim and Fill test was applied to estimate publication bias, and sensitivity analysis was performed to assess the influence of individual studies on the overall estimate.Results: Nine studies met the inclusion and exclusion criteria for this analysis. In this study, the prevalence of BKV, JCV, HPyV7, KIV, WUV, SV40, and TSV in breast cancer patients was found to be 0%. By combining the results of these studies, the prevalence of PyV, MCV, and HPyV6 in breast cancer patients was 11%, 4%, and 1%, respectively.Conclusion: The meta-analysis presented here provides an exhaustive overview of the current literature on the prevalence of polyomaviruses in breast cancer patients. Findings indicate a potentially stronger association between PyV and breast cancer than other human polyomaviruses.","PeriodicalId":13568,"journal":{"name":"Infectious Agents and Cancer","volume":"20 1","pages":"14"},"PeriodicalIF":3.1000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881251/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Agents and Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13027-025-00644-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Breast cancer is a major global health problem worldwide, affecting more than 2.25 million women annually. The disease is influenced by various factors, including some viruses, gender, age, and family history. This study aimed to conducting a comprehensive systematic review and meta-analysis of existing studies on the polyomaviruses in breast cancer.

Methods: This systematic review and meta-analysis aimed to provide an evidence-based analysis of the relationship between polyomaviruses and breast cancer. The global online databases were used to identify relevant studies published from 2000 to July 2024. The quality of each article was assessed using the Newcastle-Ottawa Scale (NOS) checklist. Data analysis was performed using STATA software, and standard errors of prevalence were calculated using the binomial distribution formula. Heterogeneity of study results was evaluated using the I-square and Q index, while publication bias was examined using the Begg's test. A random effects model was used to determine prevalence rates, and a forest plot diagram was used to present results with 95% confidence intervals. The Trim and Fill test was applied to estimate publication bias, and sensitivity analysis was performed to assess the influence of individual studies on the overall estimate.

Results: Nine studies met the inclusion and exclusion criteria for this analysis. In this study, the prevalence of BKV, JCV, HPyV7, KIV, WUV, SV40, and TSV in breast cancer patients was found to be 0%. By combining the results of these studies, the prevalence of PyV, MCV, and HPyV6 in breast cancer patients was 11%, 4%, and 1%, respectively.

Conclusion: The meta-analysis presented here provides an exhaustive overview of the current literature on the prevalence of polyomaviruses in breast cancer patients. Findings indicate a potentially stronger association between PyV and breast cancer than other human polyomaviruses.

查看原文本刊更多论文

多瘤病毒与乳腺癌风险：系统回顾和荟萃分析

背景：乳腺癌是世界范围内一个主要的全球性健康问题，每年影响超过225万妇女。该病受多种因素影响，包括某些病毒、性别、年龄和家族史。本研究旨在对乳腺癌中多瘤病毒的现有研究进行全面的系统回顾和荟萃分析。方法：本系统综述和荟萃分析旨在提供多瘤病毒与乳腺癌之间关系的循证分析。使用全球在线数据库识别2000年至2024年7月发表的相关研究。每篇文章的质量采用纽卡斯尔-渥太华量表（NOS）检查表进行评估。采用STATA软件进行数据分析，采用二项分布公式计算患病率的标准误差。使用i平方和Q指数评估研究结果的异质性，使用贝格检验检查发表偏倚。使用随机效应模型来确定患病率，并使用森林图来呈现具有95%置信区间的结果。采用Trim and Fill检验估计发表偏倚，并进行敏感性分析评估个别研究对总体估计的影响。结果：9项研究符合本分析的纳入和排除标准。本研究发现乳腺癌患者中BKV、JCV、HPyV7、KIV、WUV、SV40和TSV的患病率为0%。综合这些研究的结果，乳腺癌患者中PyV、MCV和HPyV6的患病率分别为11%、4%和1%。结论：本文提出的荟萃分析提供了关于乳腺癌患者中多瘤病毒患病率的当前文献的详尽概述。研究结果表明，与其他人类多瘤病毒相比，PyV与乳腺癌之间可能存在更强的关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious Agents and Cancer ONCOLOGY-IMMUNOLOGY

CiteScore

5.80

自引率

2.70%

发文量

期刊介绍： Infectious Agents and Cancer is an open access, peer-reviewed online journal that encompasses all aspects of basic, clinical, epidemiological and translational research providing an insight into the association between chronic infections and cancer. The journal welcomes submissions in the pathogen-related cancer areas and other related topics, in particular: • HPV and anogenital cancers, as well as head and neck cancers; • EBV and Burkitt lymphoma; • HCV/HBV and hepatocellular carcinoma as well as lymphoproliferative diseases; • HHV8 and Kaposi sarcoma; • HTLV and leukemia; • Cancers in Low- and Middle-income countries. The link between infection and cancer has become well established over the past 50 years, and infection-associated cancer contribute up to 16% of cancers in developed countries and 33% in less developed countries. Preventive vaccines have been developed for only two cancer-causing viruses, highlighting both the opportunity to prevent infection-associated cancers by vaccination and the gaps that remain before vaccines can be developed for other cancer-causing agents. These gaps are due to incomplete understanding of the basic biology, natural history, epidemiology of many of the pathogens that cause cancer, the mechanisms they exploit to cause cancer, and how to interrupt progression to cancer in human populations. Early diagnosis or identification of lesions at high risk of progression represent the current most critical research area of the field supported by recent advances in genomics and proteomics technologies.